158 related articles for article (PubMed ID: 18269248)
1. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Ember B; Kamenecka T; LoGrasso P
Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic characterization for c-jun-N-Terminal Kinase 1alpha1.
Ember B; LoGrasso P
Arch Biochem Biophys; 2008 Sep; 477(2):324-9. PubMed ID: 18559253
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
4. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175
[TBL] [Abstract][Full Text] [Related]
5. Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.
Hendriks BS; Seidl KM; Chabot JR
BMC Syst Biol; 2010 Mar; 4():23. PubMed ID: 20230629
[TBL] [Abstract][Full Text] [Related]
6. Kinetic mechanism for p38 MAP kinase.
LoGrasso PV; Frantz B; Rolando AM; O'Keefe SJ; Hermes JD; O'Neill EA
Biochemistry; 1997 Aug; 36(34):10422-7. PubMed ID: 9265622
[TBL] [Abstract][Full Text] [Related]
7. Fibronectin gene expression in aortic regurgitation: relative roles of mitogen-activated protein kinases.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Ene AR; Herrold EM; Dumlao TF; Beltran F; Borer JS
Cardiology; 2009; 113(4):291-8. PubMed ID: 19299894
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide.
Ngoei KR; Catimel B; Church N; Lio DS; Dogovski C; Perugini MA; Watt PM; Cheng HC; Ng DC; Bogoyevitch MA
Biochem J; 2011 Mar; 434(3):399-413. PubMed ID: 21162712
[TBL] [Abstract][Full Text] [Related]
9. Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors.
Niu L; Chang KC; Wilson S; Tran P; Zuo F; Swinney DC
Biochemistry; 2007 Apr; 46(16):4775-84. PubMed ID: 17397142
[TBL] [Abstract][Full Text] [Related]
10. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia.
Morioka N; Tanabe H; Inoue A; Dohi T; Nakata Y
Neurochem Int; 2009 Sep; 55(4):226-34. PubMed ID: 19524113
[TBL] [Abstract][Full Text] [Related]
11. Identification of small-molecule inhibitors of the JIP-JNK interaction.
Chen T; Kablaoui N; Little J; Timofeevski S; Tschantz WR; Chen P; Feng J; Charlton M; Stanton R; Bauer P
Biochem J; 2009 May; 420(2):283-94. PubMed ID: 19243309
[TBL] [Abstract][Full Text] [Related]
12. Identification of the critical features of a small peptide inhibitor of JNK activity.
Barr RK; Kendrick TS; Bogoyevitch MA
J Biol Chem; 2002 Mar; 277(13):10987-97. PubMed ID: 11790767
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
14. Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun).
Figuera-Losada M; LoGrasso PV
J Biol Chem; 2012 Apr; 287(16):13291-302. PubMed ID: 22351776
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
[TBL] [Abstract][Full Text] [Related]
16. Identification of human myometrial target genes of the c-Jun NH2-terminal kinase (JNK) pathway: the role of activating transcription factor 2 (ATF2) and a novel spliced isoform ATF2-small.
Bailey J; Europe-Finner GN
J Mol Endocrinol; 2005 Feb; 34(1):19-35. PubMed ID: 15691875
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of melanoma growth and metastasis by ATF2-derived peptides.
Bhoumik A; Gangi L; Ronai Z
Cancer Res; 2004 Nov; 64(22):8222-30. PubMed ID: 15548688
[TBL] [Abstract][Full Text] [Related]
18. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK.
Barr RK; Boehm I; Attwood PV; Watt PM; Bogoyevitch MA
J Biol Chem; 2004 Aug; 279(35):36327-38. PubMed ID: 15208323
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A.
Hines AC; Cole PA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2951-4. PubMed ID: 15125966
[TBL] [Abstract][Full Text] [Related]
20. The JNK1/JNK3 interactome--contributions by the JNK3 unique N-terminus and JNK common docking site residues.
Chen WK; Yeap YY; Bogoyevitch MA
Biochem Biophys Res Commun; 2014 Oct; 453(3):576-81. PubMed ID: 25301550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
